5 questions about FDA-compliant temperature mapping
A conversation with Jakob Konradsen, author of Mastering Temperature Mapping
What does the FDA actually expect from your mapping program in 2026? In this session, Devin Kelley sits down with Jakob Konradsen to answer the most pressing questions about FDA-aligned mapping.
Date: June 17, 2026
There is no prescriptive FDA mapping standard...
FDA's approach is risk-based, which gives flexibility – but also ambiguity – and less to point at when an inspector challenges a decision.
So, what is the FDA actually looking for in thermal mapping?
What triggers a re-mapping? When is temperature-only no longer enough? How do you defend a mapping decision to an inspector when the guidance does not prescribe a method? These are the questions that surface in every audit, every facility expansion, and every internal QA review.
In this session, Devin Kelley and Jakob Konradsen work through five of them.
Five questions, five concrete answers you can act on tomorrow.
Sign up now
What does the FDA actually expect from your mapping program in 2026?
When: June 17, 2026
- 9:00 a.m. CDT
- 10:00 a.m. EDT
- 4:00 p.m. CEST
Key takeaways
- Where FDA warning letters are flagging mapping-related issues
- The steps that your mapping program should follow to live up to FDA requirements
- What should trigger re-mapping under FDA expectations – and what should no
- Live Q&A with Jakob Konradsen, where you can get answers to your own questions
About the speakers
Jakob Konradsen is author of Mastering Temperature Mapping and co-founder and Chief Quality Officer at Eupry. He has spent more than a decade building GxP-compliant mapping, monitoring, and calibration programs for pharmaceutical pharma, biotech firms, and pharma logistics providers across Europe and NA. Jakob is one of the field's most direct voices on what regulators actually expect of mapping programs and regularly shares hands-on advice through webinars, podcasts, and practical guides.
Devin Kelley is US GTM lead at Eupry and will host the conversation with Jakob. He works directly with QA and validation teams at US pharma manufacturers, CDMOs, and logistics providers, spending most of his time in conversations US GxP teams and bringing the operational context for the questions this session sets out to answer.
